| Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2 … MA Bookman, KM Darcy, D Clarke-Pearson, RA Boothby, IR Horowitz Journal of clinical oncology 21 (2), 283-290, 2003 | 731 | 2003 |
| Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study C Aghajanian, MW Sill, KM Darcy, B Greer, DS McMeekin, PG Rose, ... Journal of clinical oncology 29 (16), 2259, 2011 | 368 | 2011 |
| Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study GF Fleming, MW Sill, KM Darcy, DS McMeekin, JT Thigpen, LM Adler, ... Gynecologic oncology 116 (1), 15-20, 2010 | 326 | 2010 |
| Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and … RJ Schilder, MW Sill, X Chen, KM Darcy, SL Decesare, G Lewandowski, ... Clinical Cancer Research 11 (15), 5539-5548, 2005 | 320 | 2005 |
| Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary … K Behbakht, MW Sill, KM Darcy, SC Rubin, RS Mannel, S Waggoner, ... Gynecologic oncology 123 (1), 19-26, 2011 | 238 | 2011 |
| Prognostic Significance of p53 Mutation and p53 Overexpression in Advanced Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study L Havrilesky, KM Darcy, H Hamdan, RL Priore, J Leon, J Bell, A Berchuck Journal of clinical oncology 21 (20), 3814-3825, 2003 | 227 | 2003 |
| Morphological and biochemical status of the mammary gland as influenced by conjugated linoleic acid: implication for a reduction in mammary cancer risk H Thompson, Z Zhu, S Banni, K Darcy, T Loftus, C Ip Cancer research 57 (22), 5067-5072, 1997 | 215 | 1997 |
| Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients … G Thomas, S Ali, FJP Hoebers, KM Darcy, WH Rodgers, M Patel, ... Gynecologic oncology 108 (2), 317-325, 2008 | 212 | 2008 |
| Clinicopathologic significance of mismatch repair defects in endometrial cancer: an NRG oncology/gynecologic oncology group study DS McMeekin, DL Tritchler, DE Cohn, DG Mutch, HA Lankes, MA Geller, ... Journal of Clinical Oncology 34 (25), 3062, 2016 | 191 | 2016 |
| A developmental atlas of rat mammary gland histology PA Masso-Welch, KM Darcy, NC Stangle-Castor, MM Ip Journal of mammary gland biology and neoplasia 5, 165-185, 2000 | 180 | 2000 |
| Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study J Farley, LM Smith, KM Darcy, E Sobel, D O’Connor, B Henderson, ... Cancer research 63 (6), 1235-1241, 2003 | 173 | 2003 |
| Current approaches and challenges in managing and monitoring treatment response in ovarian cancer CS Marcus, GL Maxwell, KM Darcy, CA Hamilton, WP McGuire Journal of Cancer 5 (1), 25, 2014 | 172 | 2014 |
| BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study JL Lesnock, KM Darcy, C Tian, JA Deloia, MM Thrall, C Zahn, ... British journal of cancer 108 (6), 1231-1237, 2013 | 167 | 2013 |
| Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro X He, M Pool, KM Darcy, SB Lim, N Auersperg, JS Coon, WT Beck Oncogene 26 (34), 4961-4968, 2007 | 147 | 2007 |
| PI3K/AKT/mTOR pathway in ovarian cancer treatment: are we on the right track? ML Gasparri, E Bardhi, I Ruscito, A Papadia, AA Farooqi, C Marchetti, ... Geburtshilfe und Frauenheilkunde 77 (10), 1095-1103, 2017 | 142 | 2017 |
| Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression … JM Rubatt, KM Darcy, A Hutson, SM Bean, LJ Havrilesky, LA Grace, ... Gynecologic oncology 112 (3), 469-474, 2009 | 134 | 2009 |
| Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study LM Randall, BJ Monk, KM Darcy, C Tian, RA Burger, SY Liao, WA Peters, ... Gynecologic oncology 112 (3), 583-589, 2009 | 132 | 2009 |
| Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells P Teng, NW Bateman, KM Darcy, CA Hamilton, GL Maxwell, CJ Bakkenist, ... Gynecologic oncology 136 (3), 554-561, 2015 | 111 | 2015 |
| Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer X He, AD Arslan, MD Pool, TT Ho, KM Darcy, JS Coon, WT Beck Oncogene 30 (3), 356-365, 2011 | 108 | 2011 |
| Multiple differentiation pathways of rat mammary stromal cells in vitro: acquisition of a fibroblast, adipocyte or endothelial phenotype is dependent on hormonal and … D Zangani, KM Darcy, PA Masso‐Welch, ES Bellamy, MS Desole, MM Ip Differentiation 64 (2), 91-101, 1999 | 106 | 1999 |
